Literature DB >> 3589970

Mortality after surgery for primary hyperparathyroidism: a follow-up of 441 patients operated on from 1956 to 1979.

M Palmér, H O Adami, R Bergström, G Akerström, S Ljunghall.   

Abstract

Four hundred forty-one patients who were operated on for primary hyperparathyroidism were observed for up to 22 years. Mortality was significantly higher than expected during the first postoperative years, for both men and women. This was predominantly due to a higher than expected incidence of diseases of the circulatory organs. The greater risk of death--compared with the expected mortality in the general patient population--appeared to decrease after the initial 5 to 8 postoperative years. However, for the entire follow-up period, the cumulative survival ratio (i.e., the ratio between the expected and the observed rates) was less than 1 for both sexes. The preoperative concentration of serum calcium did not influence the survival rates. The findings are consistent with the hypothesis that untreated hyperparathyroidism carries an increased risk of death, particularly from cardiovascular diseases but that this risk is gradually reduced after surgery.

Entities:  

Mesh:

Year:  1987        PMID: 3589970

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  41 in total

Review 1.  Clinical spectrum of primary hyperparathyroidism.

Authors:  J P Bilezikian; S J Silverberg
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

2.  Effect of parathyroidectomy on subclinical cardiovascular disease in mild primary hyperparathyroidism.

Authors:  M D Walker; T Rundek; S Homma; M DiTullio; S Iwata; J A Lee; J Choi; R Liu; C Zhang; D J McMahon; R L Sacco; S J Silverberg
Journal:  Eur J Endocrinol       Date:  2012-06-01       Impact factor: 6.664

Review 3.  Primary hyperparathyroidism: a surgical perspective.

Authors:  M H Wheeler
Journal:  Ann R Coll Surg Engl       Date:  1998-09       Impact factor: 1.891

4.  Cardiac structure and functions in patients with asymptomatic primary hyperparathyroidism.

Authors:  B Aktas Yılmaz; A Akyel; E Kan; U Ercin; Y Tavil; A Bilgihan; N Cakır; M Arslan; F Balos Toruner
Journal:  J Endocrinol Invest       Date:  2013-05-10       Impact factor: 4.256

5.  Treatment for mild hyperparathyroidism.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-14

6.  Evaluation of subclinical coronary atherosclerosis in mild asymptomatic primary hyperparathyroidism patients.

Authors:  Alper Kepez; Ayla Harmanci; Tuncay Hazirolan; Mehlika Isildak; Ugur Kocabas; Ahmet Ates; Orcun Ciftci; Lale Tokgozoglu; Alper Gürlek
Journal:  Int J Cardiovasc Imaging       Date:  2008-09-11       Impact factor: 2.357

Review 7.  Derangement of glucose metabolism in hyperparathyroidism.

Authors:  M Procopio; G Borretta
Journal:  J Endocrinol Invest       Date:  2003-11       Impact factor: 4.256

8.  Primary hyperparathyroidism: epidemiology, diagnosis and clinical picture.

Authors:  S Ljunghall; P Hellman; J Rastad; G Akerström
Journal:  World J Surg       Date:  1991 Nov-Dec       Impact factor: 3.352

Review 9.  Asymptomatic primary hyperparathyroidism.

Authors:  B J Harrison; M H Wheeler
Journal:  World J Surg       Date:  1991 Nov-Dec       Impact factor: 3.352

10.  Surgical treatment of primary hyperparathyroidism: an institutional perspective.

Authors:  J A van Heerden; C S Grant
Journal:  World J Surg       Date:  1991 Nov-Dec       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.